Open

CD19 CAR T-cells containing a Safety Switch to Treat Relapsed/Refractory B-cell Lymphoma

Researchers are studying different doses of a therapy (CD19 CAR T-cells) to find the dose that is both the most effective and the safest for patients with relapsed or refractory B-cell lymphoma.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

The study involves blood draws, blood tests, biopsies, procedures, imaging/scanning and follow -up visits. Participation involves three days of treatment that will prepare your body to accept the study treatment cells better. You will then return to the clinic for one day of study cell treatment. After treatment, you will have clinic visits for checkup tests and assessment including lab tests and imaging of your tumor. You will continue follow up visits based on how well you have responded to the study treatment.

Incentives

In-person visits:
Minimum of 14 through first year of participation; likely more depending on side effects

Phone or online visits:
Visits all in person unless disease has worsened, then can be contacted by phone during follow up

Total length of participation:
1 year for treatment and initial follow-up, long term follow-up for 15 years

Looking for Specific Volunteers

Able to participate:

You have been diagnosed with B-cell non-Hodgkin lymphoma with/without CNS Involvement
You have relapsed or refractory disease after at least 1/2 prior line of therapies

Not eligible if:

You are taking corticosteroids at doses of 10 mg or more of prednisone
You have history of intolerance to fludarabine
You have weakened heart muscle, as evidenced by a left ventricular ejection fraction (LVEF)

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

UNC Immunotherapy
UNCImmunotherapy@med.unc.edu

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Natalie Grover
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lymphoma)

IRB Number

18-1621

ClinicalTrials.gov

NCT03696784

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.